Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-653 in Treatment-Resistant Depression (maintenance after ketamine)
2017-002232-16Phase 2Terminated
- Sponsor
- Takeda
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing TAK-653 arm with Placebo arm (2 arms). Started Sep 2017; status: terminated.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2017-002232-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002232-16.